Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

ClinicalTrials.gov ID: NCT04376684

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04376684. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease. The study is being conducted in 2 parts (Part 1 and Part 2). Otilimab is a human monoclonal anti-granulocyte macrophage colony stimulating factor (GM-CSF) antibody that has not previously been tested in participants with severe pulmonary COVID-19 related disease in Part 1. The aim of this study is to evaluate the benefit-risk of a single infusion of otilimab in the treatment of hospitalized participants with severe COVID-19 related pulmonary disease with new onset hypoxia requiring significant oxygen support or requiring early invasive mechanical ventilation (less than or equal to \[\<=\] 48 hours before dosing). Participants will be randomized to receive a single intravenous (IV) infusion of otilimab or placebo, in addition to standard of care.

Study identification

NCT ID
NCT04376684
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,156 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 28, 2020 (Actual)
Primary completion
Jul 15, 2021 (Actual)
Completion
Aug 16, 2021 (Actual)
Last update posted
Sep 23, 2024

2020 – 2021

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
GSK Investigational Site Mobile Alabama 36608 —
GSK Investigational Site Little Rock Arkansas 72205 —
GSK Investigational Site Sacramento California 95819 —
GSK Investigational Site Torrance California 90502 —
GSK Investigational Site Gainesville Florida 32608 —
GSK Investigational Site Winfield Illinois 60190 —
GSK Investigational Site Baltimore Maryland 21201 —
GSK Investigational Site Germantown Maryland 20876 —
GSK Investigational Site Silver Spring Maryland 20910 —
GSK Investigational Site Saint Louis Park Minnesota 55426 —
GSK Investigational Site Saint Paul Minnesota 55101 —
GSK Investigational Site Jackson Mississippi 39216 —
GSK Investigational Site Reno Nevada 89502 —
GSK Investigational Site Buffalo New York 14215-1199 —
GSK Investigational Site Charlotte North Carolina 28203 —
GSK Investigational Site Toledo Ohio 43608 —
GSK Investigational Site Doylestown Pennsylvania 18901 —
GSK Investigational Site Philadelphia Pennsylvania 19140 —
GSK Investigational Site Roanoke Virginia 24017 —
GSK Investigational Site Tacoma Washington 98405 —
GSK Investigational Site Milwaukee Wisconsin 53295 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04376684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 23, 2024 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.